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Malignancy 
development 
after long-term 
immunosuppression
Successful organ transplantation 
is now the rule rather than the 
exception, thanks to powerful 
immunosuppression drugs. However, 
no treatment is without side eff ects; 
in the case of immunosuppression, 
there has been increasing concern 
regarding new malignancies that 
may develop in patients receiving 
this treatment. Wimmer et al., as 
they report in this issue, analyzed the 
incidence of malignancies that develop 
in transplant patients during a period 
of almost 30 years. Th ey found the 
cumulative incidence of malignancies 
in renal transplant recipients to be 
50% — almost twice as much as in the 
control group — with the risk of cancer 
increased about fourfold. Th e tumors 
most frequently observed were skin, 
kidney, and oropharyngeal cancers. 
Although all immunosuppression drugs 
seemed to be equally associated with 
tumor rates, rapamycin had a slightly 
lower association. With the increasing 
success of these treatments, the risks of 
increased malignancies need to receive 
much more attention and will hopefully 
inspire scientists to develop newer and 
safer therapies. See page 1271.
Role of PTH in vascular 
calcification
Vascular calcifi cation, a serious 
complication of end-stage renal disease 
(ESRD), has many potential causes, 
including hyperphosphatemia and 
hyperparathyroidism. To test for a 
direct role of high parathyroid hormone 
(PTH) levels in vascular calcifi cation, 
Neves et al. examined the independent 
roles of hyperphosphatemia, 
hyperparathyroidism, and renal failure. 
Th ey infused parathyroidectomized 
animals with high levels of PTH and 
changed the dietary phosphate in 
control rats and in those with renal 
failure produced by 5/6 nephrectomy. 
All animals receiving high-PTH 
infusions developed intense aortic 
medial calcifi cation, and some animals 
had coronary calcifi cation as well. Th e 
deposition of calcium in the media 
of arteries is a hallmark of human 
vascular calcifi cation in ESRD. Several 
of these animal models developed 
hyperphosphatemia with or without 
hypercalcemia, yet vascular calcifi cation 
correlated best with high levels of PTH 
regardless of whether the animals had 
kidney failure. Th ese studies highlight 
the need to control hyperparathyroidism 
in patients with kidney failure as a 
preventive measure for this serious 
complication. See page 1262.
ANCAs and 
immunosuppression
In many severe cases of vasculitis, 
the development of antineutrophil 
cytoplasmic antibodies (ANCAs) 
is a serious sign that oft en presages 
rapid deterioration of kidney 
function. Even worse, transplanted 
kidneys in such patients are also 
sometimes aff ected. Gera et al. 
studied 35 transplant recipients with 
previous diagnoses of Wegener’s 
granulomatosis and microscopic 
polyangiitis, some of whom had 
ANCAs at the time of transplantation. 
Th e patients were treated by standard 
immunosuppression, although without 
the use of a standardized regimen. Th e 
patients had very good graft  survival 
5 years aft er transplantation regardless of 
the presence of ANCAs. A few patients 
had relapses of vasculitis, which did 
not aff ect their kidneys and responded 
well to treatment. Th ese studies show 
that transplantation and its consequent 
immunosuppression regime are 
well tolerated in patients with severe 
vasculitis and lead to excellent results of 
graft  survival. See page 1296.
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1 In case of multiple or recurrent tumors
only the first tumor was counted
Absolute numbers of tumors detected 
in renal transplant recipients. BCC, basal-
cell carcinoma; CA, cancer; CNS, central 
nervous system; PTLD, post-transplant 
lymphoproliferative disorder; SCC, squamous-
cell carcinoma; Tx, transplanted. 
